TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in ...
Regeneron Pharmaceuticals’ first-in-class investigational allergen-blocking monoclonal antibodies (mAbs) met their primary endpoints in two Phase III trials in adults with moderate-to-severe cat or ...
Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts ...
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. On September 17, 2025, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on September 8 the results evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results